Abstract Number: 1691 • 2019 ACR/ARP Annual Meeting
Efficacy of TNF α Inhibitors for Refractory Vascular Behcet’s Disease: A Multicenter Observational Study of 27 Patients
Background/Purpose: Vascular involvement is one of the major causes of morbidity and mortality in Behcet’s Disease (BD) patients. Immunosuppressive (IS) agents are the mainstay of…Abstract Number: 1694 • 2019 ACR/ARP Annual Meeting
Pharmacogenetics and Pharmacodynamics of Response to Apremilast in a Phase 3 Clinical Study in Subjects with Active Behçet’s Disease
Background/Purpose: This was an exploratory analysis of genetic polymorphisms, plasma biomarkers, and blood leukocytes with clinical response in the phase 3 clinical study CC-10004-BCT-002 (NCT02307513).Methods:…Abstract Number: 1695 • 2019 ACR/ARP Annual Meeting
Apremilast in Combination vs Monotherapy for Refractory Oral And/or Genital Ulcers in Behçet’s Disease: National Multicenter Study of 51 Cases
Background/Purpose: Oral and/or genital aphthous ulcers are the most common symptoms of Behçet´s disease (BD), and are often refractory to conventional treatment. The inhibitor of…Abstract Number: 1696 • 2019 ACR/ARP Annual Meeting
Is the Risk of Tuberculosis Increased in Behçet’s Disease Compared to Other Rheumatological Disorders After Anti-TNF-α Treatment?
Background/Purpose: Tumor necrosis factor (TNF)-α inhibitors are extensively utilized in the treatment of inflammatory rheumatic diseases. These agents increase the risk of tuberculosis (TB), especially…Abstract Number: 1697 • 2019 ACR/ARP Annual Meeting
Efficacy of Apremilast for Oral Ulcers Associated with Active Behçet’s Syndrome over 64 Weeks: Long-term Results from the Japanese Subgroup in a Phase III Study
Background/Purpose: Behçet’s syndrome is a chronic, multi-system, variable vessel vasculitis characterized by painful, recurrent oral ulcers (OU) that can be disabling and may impair quality…Abstract Number: 1698 • 2019 ACR/ARP Annual Meeting
Development of Machine Learning Models (Artificial Neural Networks) for Prediction of Vision Threatening Behçet’s Disease
Background/Purpose: Ocular involvement in Behçet’s Disease (BD) is associated with chronic damage and high morbidity; however, limited evidence is available on risk factors to recognize…Abstract Number: 1699 • 2019 ACR/ARP Annual Meeting
Disease Course of Behçet’s Syndrome Patients Not Fulfilling International Study Group Criteria at Presentation
Background/Purpose: Behçet’s syndrome (BS) shows a heterogeneous phenotype involving many organ systems and is diagnosed by recognizing the coexisting manifestations. Patients may have major organ…Abstract Number: 1700 • 2019 ACR/ARP Annual Meeting
Clinical Characteristics and the Level Disease Activity of Behcet´s Disease in China: A Study Based on Smart System of Disease Management (SSDM)
Background/Purpose: Behcet´s disease (BD) is a systemic autoimmune disease that affects multiple organ systems with recurrent oral ulcers, genital ulcers and skin lesions, which might…Abstract Number: 1701 • 2019 ACR/ARP Annual Meeting
Amyloidosis in Behcet’s Disease: Experience of a Vasculitis Centre at Silk Road
Background/Purpose: Bechet’s disease (BD) is a vasculitis characterized by oral aphtae, genital ulcers, skin lesions, uveitis and with less frequent involvement of the neurological, vascular…Abstract Number: 1705 • 2019 ACR/ARP Annual Meeting
Cyclophosphamide Therapy for the Neurologic Involvement of Behçet’s Disease – Is It Superior to Azathioprine in Preventing Relapses?
Background/Purpose: Neurologic involvement is one of the most serious cause of long-term morbidity and mortality in Behçet’s disease (BD). To date, no controlled trials have…Abstract Number: 1706 • 2019 ACR/ARP Annual Meeting
HLA-B*51 and Its Subtypes in Brazilian Patients with Behçet’s Disease
Background/Purpose: HLA-B*51 is considered the genetic marker mostly associated with Behçet's disease (BD), mainly in countries of the silk route, where its prevalence ranges from…Abstract Number: 1720 • 2019 ACR/ARP Annual Meeting
Pentoxifylline Gel for Oral Ulcers in Patients with Behçet’s Syndrome
Background/Purpose: Oral ulcers, the hallmark lesion of Behçet’s syndrome (BS) can be disabling and impair eating, drinking and speaking. Despite recent advances in systemic medications…Abstract Number: 440 • 2019 ACR/ARP Annual Meeting
Disease Activity and Quality of Life in Behçet’s Syndrome: The Role of Patient Reported Outcome
Background/Purpose: Behçet’s syndrome (BS) is a systemic vasculitis, characterised by recurrent oro-genital ulcers, ocular inflammation and skin manifestations; articular, vascular, gastro-enteric and neurological involvement may…Abstract Number: 1932 • 2019 ACR/ARP Annual Meeting
Genetic Evidence for Recent Positive Selection of the HLA-B*51:01 Allele in the Turkish Population, a Population with a High Prevalence of HLA-B*51-Associated Behçet’s Disease
Background/Purpose: The Turkish population has one of the highest world-wide prevalence’s of the genetically complex inflammatory Behçet’s disease (BD), estimated as 4 affected per 1000…Abstract Number: 946 • 2019 ACR/ARP Annual Meeting
Improvements in Disease Activity and Quality of Life for up to 64 Weeks in Patients with Behçet’s Syndrome: Results from a Phase III Study
Background/Purpose: Behçet’s syndrome is a chronic, multi-system inflammatory disorder characterized by painful, recurrent oral ulcers (OU) that can impair quality of life (QoL). Apremilast (APR),…
- 1
- 2
- 3
- …
- 12
- Next Page »